Immunoassays

News on immunoassay systems and applications.

The point-of-care test will use the companies' respective technologies and detect two protein biomarkers of inflammation and immune system activity.

Changes in physician behavior around monitoring patient response to therapeutic monoclonal antibodies is increasing demand for clinical testing of these drugs.

The test measures a number of protein biomarkers, including a proprietary antibody, to diagnose prostate cancer and determine its aggressiveness.

Cardiac immunoassays paced revenue growth in Q4. The firm also saw an 88 percent jump in total revenues for 2018, supported by 43 percent growth in molecular diagnostics. 

The study is part of a broader effort by academic and industry researchers to develop blood-based tests for easier, less expensive Alzheimer's screening.